Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. (Q34492647)

2 August 2017

1 reference

title

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. (English)

1 reference

2 August 2017

1 reference

metastatic breast cancer

1 reference

1 reference

2

Caroline M Perry

1 reference

2 August 2017

1

Kate McKeage

1 reference

2 August 2017

1 January 2002

1 reference

2 August 2017

1 reference

2 August 2017

62

1 reference

2 August 2017

1

1 reference

2 August 2017

209-243

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200262010-00008

2 August 2017

0 references

cites work

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

1 reference

12 December 2020

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

1 reference

12 December 2020

Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.

1 reference

12 December 2020

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

12 December 2020

1 reference

12 December 2020

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

12 December 2020

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

12 December 2020

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

12 December 2020

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

1 reference

12 December 2020

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

12 December 2020

Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer

1 reference

12 December 2020

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

Bleeding risk with trastuzumab (Herceptin) treatment

1 reference

12 December 2020

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

12 December 2020

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.

1 reference

12 December 2020

Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study

1 reference

12 December 2020

Experts debate value of HER2 testing methods

1 reference

12 December 2020

Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

1 reference

12 December 2020

Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model

1 reference

12 December 2020

Pharmacology and therapeutic use of trastuzumab in breast cancer

1 reference

12 December 2020

Developments in chemotherapy of breast cancer

1 reference

12 December 2020

Treatment of breast cancer

1 reference

12 December 2020

Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer

1 reference

12 December 2020

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Trastuzumab and breast cancer

1 reference

12 December 2020

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

12 December 2020

Her2 and trastuzumab in breast cancer

1 reference

12 December 2020

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

12 December 2020

From the molecule to the clinic--inhibiting HER2 to treat breast cancer

1 reference

12 December 2020

Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines

1 reference

12 December 2020

First-line Herceptin monotherapy in metastatic breast cancer

1 reference

12 December 2020

Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer.

1 reference

12 December 2020

Herceptin in the adjuvant setting: phase III trials begin

1 reference

12 December 2020

Can HER2 status predict response to cancer therapy?

1 reference

12 December 2020

10.2165/00003495-200262010-00008

Identifiers

DOI

1 reference

PubMed ID

11790161

Dimensions Publication ID

2 August 2017

0 references

1 reference

PubMed ID

11790161